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Cancer causes more than 7 million deaths worldwide,with lung cancer responsible for 1.2 million deaths.
The disease is costly to diagnose and manage and results in
substantial morbidity and mortality. The overall 5-year
survival rate for lung cancer remains 14%. Fluoro-2-
deoxy-D-glucose positron emission tomography (FDG-
PET) scanning adds another dimension to the anatomic
information available from computed tomographic scan-
ning in the treatment of these patients. The glucose analog
FDG concentrates in tumor cells in proportion to several
characteristics.
Specific parameters related to local tumor aggressive-
ness, including vascular invasion and plural involvement, and
tumor proliferative potential and differentiation, are major
factors contributing to increased lesion FDG uptake. There is
a progression of FDG avidity, with the highest uptake in fully
differentiated tumors, less in moderately differentiated tu-
mors, and the least in well differentiated lesions. Similarly,
there is a progression in histologic type, with the highest
uptake seen in large cells, intermediate uptake in squamous
cells and adenocarcinoma, and the lowest uptake observed in
bronchoalveolar carcinoma.
There are several applications of FDG-PET for patients
with known or suspected lung cancer, including: 1) evalua-
tion of solitary pulmonary nodules; 2) initial evaluation of
patients with biopsy-proven lung cancer to identify nodal
disease and distant metastases for staging; and 3) serial
evaluation of patients to determine the effectiveness of che-
motherapy. An additional application is the prognostic value
of serial FDG-PET images. Before neo-adjuvant chemotherapy
in patients with stage III non-small cell lung cancer, for example,
a 60% decrease in standard update value was associated with a
5-year survival rate of 60%. However, when patients had less
than a 25% decrease in standard update value, the 5-year
survival rate was less than 5%. Similarly, FDG-PET scanning
predicted disease-free survival during subsequent 4 years, even
for patients with stage I non-small cell lung cancer.
In solitary pulmonary nodules (with lesions 7 mm or
larger), FDG has a sensitivity of 84% and a specificity of
82%. These data enhance the specificity of contrast coeffi-
cient of Thermal Expansion enhancement, reducing the need
for needle biopsy for a significant number of these patients.
In addition to neoplasms, FDG is concentrated in be-
nign conditions such as inflammation as a result of pneumo-
nia, bronchiectasis, infection (such as tuberculosis, histoplas-
mosis, aspergillosis, and aspergillosis), silicosis, apoptosis,
and sarcoidosis.
To avoid misdiagnosis, it is important to examine both
the computed tomographic scan and the FDG scan to define
lesion characteristics that can assist in the distinction between
benign and malignant disease.
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